Last reviewed · How we verify
NCT06714188: IPF-PPC
Application of Personalized Palliative Care in Patients With Newly Diagnosed Idiopathic Pulmonary Fibrosis
trial in IPF in 30 participants. Completed in 30 June 2025.
17 July 2024
Quick facts
| Lead sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 30 |
| Start date | 19 September 2023 |
| Primary completion | 17 July 2024 |
| Estimated completion | 30 June 2025 |
| Sites | 1 location across Italy |
Conditions studied
- IPF — all drugs for IPF →
Sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna — full company profile →
Who can join
18 and older, any sex, with IPF. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to develop a tool that helps the medical-nursing team in the identification of the real palliative care needs of each individual patient. Patients with newly diagnosed Idiopathic Pulmonary Fibrosis will be asked just a few simple questions in order to place them at the most appropriate level of palliative care (PC) even before the first medical contact. This would not only optimize resource allocation (e.g., allowing patients with low palliative needs to be assessed solely by the PC nurse), but also benefit patients who have difficulty leaving their homes by enabling them to receive evaluation and palliative care directly at home rather than after a hospital assessment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06714188
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for IPF
Currently open trials in the same condition.
- NCT06747923 — SB17170 Phase 2 Trial in IPF Patients · Phase 2 · recruiting
- NCT07139925 — Assessment of Self-Care in Patients With Idiopathic Pulmonary Fibrosis (IPF) · active not recruiting
- NCT06644144 — P4O2 ILD Extension · recruiting
- NCT06714812 — Diarrheal Adverse Events in Caucasian Patients With Idiopathic Pulmonary Fibrosis Undergoing Treatment With Nintedanib · active not recruiting
- NCT05570058 — Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis · Phase 2 · active not recruiting
Other IRCCS Azienda Ospedaliero-Universitaria di Bologna trials
Trials by the same sponsor.
- NCT06718049 — Role of Interleukin 18 (IL-18) and Interleukin 18 Binding Protein (IL-18BP) in the Diagnostic Work-up of Systemic Juveni · not yet recruiting
- NCT07490392 — Growth and Endocrinological Outcomes in Patients Who Underwent or Did Not Undergo Haematopoietic Stem Cell Transplantati · not yet recruiting
- NCT07483853 — Reliability and Validation of the WB-MRI Radiological Score in CRMO · recruiting
- NCT07479121 — These Studies Assess Surgeons' Physical and Ergonomic Workloads. Study 1 Compares Laparoscopic vs. Hugo RAS Robotic Appr · NA · not yet recruiting
- NCT07471009 — Development of Patient Derived Xenografts (PDXs) and Analysis of Tyrosine Kinase Receptor Expression in Patients With Sq · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06714188 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Last refreshed: 2 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06714188.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing